Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer.

Betteridge, Z; Priest, L; Cooper, R; McHugh, N; Blackhall, Fiona H; Lamb, J

dc.contributor.author	Betteridge, Z
dc.contributor.author	Priest, L
dc.contributor.author	Cooper, R
dc.contributor.author	McHugh, N
dc.contributor.author	Blackhall, Fiona H
dc.contributor.author	Lamb, J
dc.date.accessioned	2018-10-15T16:55:24Z
dc.date.available	2018-10-15T16:55:24Z
dc.date.issued	2018-08-09
dc.identifier.citation	Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer. 2018, 20(1): 176 Arthritis Res Ther	en
dc.identifier.issn	1478-6362
dc.identifier.pmid	30092841
dc.identifier.doi	10.1186/s13075-018-1678-9
dc.identifier.uri	http://hdl.handle.net/10541/621273
dc.description.abstract	The close temporal association between onset of some connective tissue diseases and cancer suggests a paraneoplastic association. Adult patients with scleroderma with anti-RNA polymerase III autoantibodies and adult patients with dermatomyositis with anti-transcriptional intermediary factor 1 (anti-TIF1) or anti-nuclear matrix protein 2 (anti-NXP2) autoantibodies have a significantly increased risk of developing cancer. Autoantibodies may serve as biomarkers for early detection of cancer and also could be relevant for prediction of responses to immune therapies. We aimed to test whether myositis and scleroderma specific or associated autoantibodies are detectable in individuals with lung cancer.
dc.language.iso	en	en
dc.rights	Archived with thanks to Arthritis research & therapy	en
dc.title	Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer.	en
dc.type	Article	en
dc.contributor.department	Department of Pharmacy and Pharmacology, University of Bath, Bath, UK	en
dc.identifier.journal	Arthritis Research & Therapy	en
refterms.dateFOA	2018-12-17T15:38:08Z
html.description.abstract	The close temporal association between onset of some connective tissue diseases and cancer suggests a paraneoplastic association. Adult patients with scleroderma with anti-RNA polymerase III autoantibodies and adult patients with dermatomyositis with anti-transcriptional intermediary factor 1 (anti-TIF1) or anti-nuclear matrix protein 2 (anti-NXP2) autoantibodies have a significantly increased risk of developing cancer. Autoantibodies may serve as biomarkers for early detection of cancer and also could be relevant for prediction of responses to immune therapies. We aimed to test whether myositis and scleroderma specific or associated autoantibodies are detectable in individuals with lung cancer.